Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)

Abstract

Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable." should be replaced with "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable." (3.0% instead of 0.3%). The publisher apologizes for any inconvenience caused by this error.